|
Mr. Chaney was appointed President of (OSI) Eyetech and Executive Vice President, OSI Pharmaceuticals in May 2006. Prior to the merger of Eyetech with OSIP, Mr. Chaney served as Chief Operating Officer of Eyetech, since August 2003. Mr. Chaney presided over all of the commercial functions critical to the Macugen launch, achieving first year sales of $185 million.
Mr. Chaney has more than 25 years of experience in the pharmaceutical industry, including from 1996 to August 2003, serving in various senior management positions at Pharmacia Corporation, a pharmaceutical company acquired by Pfizer in April 2003. He was responsible for the launch of a number of ophthalmic products, including Tecnis®, Healon5, Xalatan and Xalcom®. More specifically, from July 2002 to August 2003, Mr. Chaney served as Vice President, Global Commercial Operations, Ophthalmology Franchise; from May 2001 to June 2002, he served as Vice President, Global Ophthalmology Business; from February 2000 to April 2001, he served as Vice President, Global Pharmaceutical Ophthalmology; from February 1998 to February 2000, he served as Business Director, Ophthalmology, North America; and from February 1996 to February 1998, he served as Director, U.S. Ophthalmology Business. He began his career as a sales representative for The Upjohn Company in 1980.
Mr. Chaney earned a double B.A. with honors in English and Biological Sciences from the University of Delaware. | 